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Abstract 
Aberrant DNA methylation is an important event in carcinogenesis. Of the various 
regions of a gene that can be methylated in cancers, the promoter is most important for 
the regulation of gene expression.  Here, we describe a microarray analysis of DNA 
methylation in the promoter regions of genes using a newly developed 
Promoter-associated Methylated DNA Amplification DNA chip (PMAD).  For each 
sample, methylated Hpa II-resistant DNA fragments and Msp I-cleaved (unmethylated 
plus methylated) DNA fragments were amplified and labeled with Cy3 and Cy5 
respectively, then hybridized to a microarray containing the promoters of 288 
cancer-related genes. Signals from Hpa II-resistant (methylated) DNA (Cy3) were 
normalized to signals from Msp I- cleaved (unmethylated plus methylated) DNA 
fragments (Cy5).  Normalized signals from lung cancer cell lines were compared to 
signals from normal lung cells.  About 10.9% of the cancer-related genes were 
hypermethylated in lung cancer cell lines.  Notably, HIC1, IRF7, ASC, RIPK3, 
RASSF1A, FABP3, PRKCDBP, and PAX3 genes were hypermethylated in most lung 
cancer cell lines examined.  The expression profile of these genes correlated to the 
methylation profile of the genes indicating that the microarray analysis of DNA 
methylation in the promoter region of the genes is convenient for epigenetic study.  
Further analysis of primary tumours indicated that the frequency of hypermethylation 
was high for ASC (82%) and PAX3 (86%) in all tumor types and high for RIPK3 in 
small cell carcinoma (57%).  This demonstrates that our PMAD method is effective for 
finding epigenetic changes in cancer.  
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Introduction 
In the human genome, most of the cytosine residues at CpG dinucleotides are 
methylated, but some remain unmethylated in specific GC-rich areas, called CpG 
islands (Antequera et al., 1990).  Although CpG islands were traditionally considered 
to be located in 5’ regions of genes and to be consistently kept unmethylated, they are 
actually located at various positions throughout genes, such as in exons and introns, or 
further downstream (Takai and Jones 2002).  The methylation of promoter regions is 
associated with a loss of gene expression and plays an important role in regulating gene 
expression.  This epigenetic event is associated with the transcriptional silencing of 
genes involved in differentiation, genomic imprinting, and X inactivation.  In cancers, 
aberrant methylation of 5’ CpG islands of some tumour suppressor genes has been 
reported (Baylin et al., 1997).   
 Techniques such as restriction landmark genomic scanning (RLGS) and a 
Representational Difference Analysis (RDA)-based method have been developed to 
scan for differences in methylation in the genome in order to identify imprinted genes 
and aberrantly methylated genes in cancer (Hatada et al., 1993; Ushijima et al., 1997).   
Recently, we and others have developed microarray-based techniques to scan for 
differences in methylation in the genome (Hatada et al., 2002; Yan et al., 2001).  Using 
these methods, methylated fragments in the genome are amplified and hybridized to 
microarrays that contain clones from libraries of CpG islands. However, methylation in 
cancer cells frequently occurs in CpG islands outside promoter regions.  In some cases, 
methylation outside the promoter induces a condensed chromatin structure of the gene 
and prevents binding of transcription factors to the promoter (Pieper 1996).  However 
in most cases methylation outside promoter regions do not repress gene transcription 
(Ushijima 2005).  To solve this problem, we cloned the promoters of genes and used 
them to make a microarray in this study.   
 Here, we describe a new method of scanning for methylation using a 
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microarray which contains promoters of 288 cancer-related genes.  We used this 
method for a methylation-based analysis of lung cancers. 
 
Materials and Methods 
Promoter-associated Methylated DNA Amplification DNA chip (PMAD) method 
Each sample was used for both amplification of Hpa II-resistant DNA and Msp 
I-cleaved DNA.  The procedure is illustrated in Fig. 1A.  For the amplification of 
methylated Hpa II-resistant DNA fragments, 0.5 μg of genomic DNA was digested 
overnight with 50 units of Hpa II.  The digests were treated with Alkaline phosphatase 
followed by fill in reaction by Klenow enzyme to block the ends of unmethylated DNA 
fragments.  Blocked DNA was digested overnight with 50 units of Msp I to cleave the 
methylated Hpa II sites followed by ligation to 11 pmol of the adaptor. The adaptor was 
prepared by annealing two oligonucleotides, AGCACTCTCCAGCCTCTCACCGAC 
and CGGTCGGTGA.  PCR was performed using 0.1 μg of each ligation mix as a 
template in a 100-μl volume containing 100 pmol of the primer 
AGCACTCTCCAGCCTCTCACCGAC and 1.25 units of GeneTaq DNA polymerase. 
The reaction mixture was incubated for 5 min at 72oC and 3 min at 94oC and subjected 
to cycles of amplification consisting of 10 s denaturation at 94oC, 30 s annealing at 
70oC and 2.5 min extension at 72oC.  The final extension was lengthened over 9.5 
min. 
 For the amplification of Msp I-cleaved (unmethylated plus methylated) DNA 
fragments, 0.5 μg of genomic DNA was digested overnight with 50 units of Msp I 
followed by ligation to 11 pmol of the adaptor. PCR was performed by the same 
procedure as was applied for the amplification of methylated Hpa II-resistant DNA 
fragments. 
To make the microarrays, PCR primers were selected from the promoter 
regions of 288 cancer-related genes (Supplementary Table 1).  All the promoter 
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sequences are at least included in one short Msp I fragment.  PCR products were 
cloned into the vector pCR2.1 (Invitrogen) and introduced into E. coli.   Each colony 
was amplified by PCR using CCAGTGTGCTGGAATTCGGC and 
ATGGATATCTGCAGAATTCGGC as primers.  The reaction mixture was incubated 
for 5 min at 94oC and subjected to 40 cycles of amplification consisting of 10 s 
denaturation at 94oC, 30 s annealing at 60oC and 1 min extension at 72oC.  Four DNA 
sequences without any homology to the human genome were also amplified as control 
spots.  Amplified DNA fragments were fixed on poly-L-lysine-coated microscope 
slides in triplicate as described (Schena et al. 1995) using a SPBIO-2000 (Hitachi 
Software Engineering Co., Ltd) arrayer.   
Amplified DNAs mixed with 10 pg of DNA complementary to control spots 
were labeled with Cy3 and Cy5 respectively, cohybridzed to the microarray, scanned 
using a Scan Array Lite (PerkinElmer) scanner, and analyzed with the software 
DNASIS Array (Hitachi Software Engineering).  Labeling efficiency was normalized 
by using the signal intensities of the control spots.  Cy3 intensity (Hpa II-resistant 
DNA fragments) was normalized to Cy5 intensity (Msp I-cleaved DNA fragments) for 
comparison among samples (normalized intensity = Cy3 intensity /Cy5 intensity).  The 
spots whose Cy5 intensities were higher than background were analyzed.  We judged 
the spots as hypermethylated compared to normal lung when their (Normalized intensity 
of cancer) / (Normalized intensity of normal) were more than 3.0 and normalized 
intensity of cancer was high enough (more than 0.2).       
 
Combined bisulfite restriction analysis (COBRA) 
Genomic DNA was treated with sodium bisulfite using a CpGenome DNA Modification 
Kit (INTERGEN) and subjected to combined bisulfite restriction analysis (COBRA).  
PCR products were digested with BsiEI (HIC1), Taq I (IRF7), Hha I (ASC), Hinf I 
(RIPK3), Hha I (RASSF1A), Hinc II (FABP3), Taq I (PRKCDBP), and Ban III (PAX3), 
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respectively.  PCRs were performed using the following primers: HIC1, 
GGTAATTGTTTTTAAAAGGGTTATTG and 
TACCCTCTAAAATAAAAACCCAAAC; IRF7, 
GTAGAGTTAAGAGTTGGGGGAGTTT and 
TATTAAACCAATATCCAAACCTAAC; ASC, 
TTTTAGTATGTGGAATTGAGGGAGT and 
AAACCTCTAAATTAAAACCCCAAAC; RIPK3, 
TTTTTGGTATTTTTTAGTTTGATGT and AACTCCTAATTCTCCAATTCCTC; 
RASSFF1A, AGTTTTTGTATTTAGGTTTTTATTG and 
AACTCAATAAACTCAAACTCCCC; FABP3, 
GTTTAGAGGTTAGGAAAGGGAGAAG and 
CAAACTAAAACTCACCCAAAAAAAA; PRKCDBP, 
AAATAGGTATATTAGGGAATTGGAG and 
AACTCCAACTATAACTCAAACAAAC; and PAX3, GGTTTTTGGATTAGGAAT 
and TAATCATCCTAAAAACAACTTC. 
 
RT-PCR  
RT-PCR was performed using the following primers: HIC1, 
GCTGCTGCAGCTCAACAACCA and GGCCGGTGTAGATGAAGTCCA; IRF7, 
TACCATCTACCTGGGCTTCG and GCTCCATAAGGAAGCACTCG; ASC, 
TGACGGATGAGCAGTACCAG and TCCTCCACCAGGTAGGACTG; RIPK3, 
CTTCCAGGAATGCCTACCAA and TCCATTTCTGTCCCTCCTTG; RASSFF1A, 
CTTCATCTGGGGCGTCGTG and CTGTGTAAGAACCGTCCTTGTTC; FABP3, 
CATCACTATGGTGGACGCTTTCC and CTCATCGAACTCCACCCCCAAC; 
PRKCDBP, AGCTCCACGTTCTGCTCTTC and CGGAGGCTCTGTACCTTCTG; and 
PAX3, CTGGAACATTTGCCCAGACT and TATCCAGGTGAAGGCGAAAC. 
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Results and Discussion 
 
We have developed a Promoter-associated Methylated DNA Amplification DNA chip 
(PMAD) for analysis of DNA methylation in the promoter regions of genes (Fig.1).  
Using this method, methylated DNA fragments can be amplified and compared.   A 
methylation-sensitive restriction enzyme Hpa II and its methylation-insensitive 
isoschizomer, Msp I, were utilized because most CpG islands contain their recognition 
sequence, “CCGG”.  For each sample, methylated Hpa II-resistant DNA fragments 
and Msp I-cleaved (unmethylated plus methylated) DNA fragments were amplified and 
labeled with Cy3 and Cy5 respectively, then hybridized to the microarray which 
contains the promoter regions of 288 cancer-related genes. Signals from Hpa II-resistant 
(methylated) DNA (Cy3) were normalized using signals from Msp I-cleaved 
(unmethylated plus methylated) DNA fragments (Cy5).   
For the amplification of methylated Hpa II-resistant DNA fragments, genomic 
DNA was cleaved with the methylation-sensitive restriction enzyme, Hpa II.  This was 
followed by the blocking of cleaved ends by alkaline phosphatase and fill in reaction.  
At this stage, unmethylated Hpa II sites were blocked.  Blocked DNA was treated with 
the methylation-resistant isoschizomer, Msp I, to cleave the methylated Hpa II sites.  
At this stage, only methylated Hpa II sites had 5’ protruding ends that could be ligated 
to an adaptor.  These ends were ligated to the adaptor followed by PCR-amplification.  
For the amplification of Msp I-cleaved (unmethylated plus methylated) DNA fragments, 
genomic DNA was cleaved with the methylation-resistant isoschizomer, Msp I, 
followed by ligation to an adaptor and PCR.  As a result, both unmethylated and 
methylated DNA fragments were amplified.  Amplified DNAs mixed with 10 pg of 
DNA complementary to control spots were labeled with Cy3 (Hpa II-resistant DNA 
fragments) and Cy5 (Msp I-cleaved DNA fragments) respectively, and cohybridized to 
the microarray, which contained the promoter regions of 288 cancer-related genes 
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including 64 reported to be hypermethylated in cancers.  Labeling efficiency was 
normalized by using the signal intensities of the four control spots whose DNA 
sequences did not have any homology to the human genome.  Cy3 intensity (Hpa 
II-resistant DNA fragments) was normalized to Cy5 intensity (Msp I-cleaved DNA 
fragments) for comparison among samples (normalized intensity = Cy3 intensity /Cy5 
intensity).   The spots whose Cy5 intensities were higher than background were 
analyzed.  We judged the spots as hypermethylated compared to normal lung when 
their (Normalized intensity of cancer) / (Normalized intensity of normal) ratio was more 
than 3.0 and normalized intensity of cancer was high enough (more than 0.2).        
 We applied PMAD to six lung cancer cell lines (1-87, A549, RERF-LCMS, 
LK79, S2, and SBC-3) and a normal lung.  Genes hypermethylated in at least two of 
six lung cancer cell lines were presented (Table 1).  On average, 10.9% of the 
cancer-related genes were hypermethylated in these cancer cell lines (Table 2).  This 
value is much higher than that described in a previous report by Yan et al. (2001) in 
breast cancer; where only 1% of regions examined were hypermethylated.  There are 
two possible explanations.  The first possibility is that these two studies reflect 
differences between cancers arising in the breast and the lung.  Consistent with this, 
the rate of methylation differed among the cancer types.  The average hypermethylated 
rate was 7.8% for adenocarcinoma (1-87, A549, RERF-LCMS) and 14.0% for small cell 
carcinoma (LK79, S-2, SBC-3), respectively (Table 2).  The second possibility is that 
genes are more liable to be hypermethylated in cancers.   
 We further analyzed the eight genes that were hypermethylated in at least five 
of the six (83%) cancer cell lines that we analyzed (Fig.2A).  These were HIC1, IRF7, 
ASC, RIPK3, RASSF1A, FABP3, PRKCDBP, and PAX3. We confirmed these results 
using the COBRA method and found that 98% of the PMAD results corresponded to the 
COBRA results (Fig.2).  Thus, the reliability of this method was demonstrated.  Next, 
we performed an expression analysis of these genes by RT-PCR (Fig.3 and Table 1).  
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The expression profile of the genes correlated to the methylation profile of the genes 
(Fig.2, 3).  This result indicates that the microarray analysis of DNA methylation in the 
promoter region of the genes is convenient for detecting methylation, which is 
responsible for their expression.  Considering that CpG islands are actually located at 
various positions throughout genes, such as in exons and introns, or further downstream 
(Takai and Jones 2002), analysis of CpG islands located in the promoter region of the 
genes is extremely convenient for epigenetic study.  Shi et al. (2002, 2003) reported 
the microarray using CpG island clones screening by hybridization of 5’ end cDNA 
library.  Although 79% of the sequences located in the promoter and first exon, others 
are out of these regions.  As comparison with this array, all genes on our array contain 
the promoter region of the genes.    
HIC1, RASSF1A, and PRKCDBP were previously reported as 
hypermethylated genes in lung cancer (Issa et al., 1997; Dammann et al., 2000; Xu et al., 
2001), but this is the first report indicating that IRF7, ASC, FABP3, and PAX3 are also 
hypermethylated in lung cancer, although these were previously known as 
hypermethylated genes in cancers other than that of the lung (Yu et al., 2003; Levine et 
al., 2003; Huynh et al., 1996; Kurmasheva et al., 2005).  Receptor-interacting 
serine-threonine kinase (RIPK) 3, which is part of the same family of RIPK1 containing 
a death domain, has never been reported to be hypermethylated in any cancers before 
our report.  Interestingly, the locations of HIC1, RIPK3, FABP3, and PRKCDBP were 
reported to lose heterozygosity in lung cancer (Konishi et al., 1998; Abujiang et al., 
1998; Chizhikov et al., 2001; Petersen et al., 1997).   
Further methylation analyses of primary tumours were performed for IRF7, 
ASC, RIPK3, FABP3, and PAX3 (Fig. 4) whose hypermethylation in lung cancers has 
not been previously reported.  The frequency of hypermethylation was high for ASC 
(82%) and PAX3 (86%).  The frequency of hypermethylation was not high for IRF7, 
RIPK3, and FABP3 compared to analysis in cell lines. However, the frequency of 
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hypermethylation of RIPK3 in small cell carcinoma was high (57%).   
Apoptosis-associated speck-like protein (ASC) is up-regulated by inflammation and 
apoptosis via the activation of caspase (Shinohara et al., 2002). In normal cells, this 
protein is localized to the cytoplasm; however, in cells undergoing apoptosis, it forms 
ball-like aggregates near the nuclear periphery. This gene is hypermethylated in breast 
cancer (Levine et al., 2003).  Paired box gene 3 (PAX3) was recently reported to be 
hypermethylated in rhabdomyosarcoma (Kurmasheva et al. 2005).  This gene is a 
member of the paired box (PAX) family of transcription factors. Members of the PAX 
family typically contain a paired box domain and a paired-type homeodomain. These 
genes play critical roles during fetal development. Mutations in paired box gene 3 are 
associated with Waardenburg syndrome, craniofacial-deafness-hand syndrome, and 
alveolar rhabdomyosarcoma. The translocation t (2; 13)(q35; q14), which represents a 
fusion of PAX3 and the forkhead gene, is a frequent finding in alveolar 
rhabdomyosarcoma (Shapiro et al. 1993).  Interestingly, loss of 2q36, where this gene 
is located, was reported in non-small cell lung cancer (NSCLC) (Petersen et al. 1997).    
Thus, we identified several interesting findings on PMAD analysis.  One of 
the merits of our method is using only cancer-related genes for a microarray.  This 
enables us to detect methylation changes occurring only in cancer-related genes.  If we 
find common epigenetic changes in cancers, it is easy to think the biological meaning of 
those changes.  However, it is true this approach miss the changes in unexpected genes.  
So it is also important to use genome-wide microarray.  However, too many changes of 
the genes of unknown function make it difficult to narrow down the targets in 
genome-wide approach.  So it is a time-consuming and expensive analysis.  On the 
other hand, our cancer-related microarray is not expensive to perform and analysis is 
easy. 
 In summary, we developed a Promoter-associated Methylated DNA 
Amplification DNA chip (PMAD) and found it very useful for analyzing DNA 
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methylation in cancers because the microarray contains critical promoter regions of 
each cancer-related gene whose methylation is highly related to the repression of the 
gene.  We found an unexpectedly high rate of hypermethylation in lung cancer cell 
lines, especially in HIC1, IRF7, ASC, RIKPK3, RASSF1A, FABP3, PRKCDBP, and 
PAX3.  This demonstrates that our PMAD method is effective for finding epigenetic 
changes in cancer.  Further analysis of primary tumours indicated that the frequency of 
hypermethylation was high for ASC (82%) and PAX3 (86%) in all tumor types and high 
for RIPK3 in small cell carcinoma (57%). 
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Legends to figures and tables 
 
Fig. 1  Schematic flowchart for the Promoter-associated Methylated DNA 
Amplification DNA chip (PMAD) method.  Me represents a methylated Hpa II site.  
Each sample was used for both amplification of Hpa II-resistant DNA and Msp 
I-cleaved DNA.  For the amplification of methylated Hpa II-resistant DNA fragments, 
genomic DNA was digested with Hpa II followed by treatment with Alkaline 
phosphatase and the Klenow enzyme to block the ends of unmethylated DNA fragments.  
Blocked DNA was digested with Msp I to cleave the methylated Hpa II sites followed 
by ligation to the adaptor. PCR was performed by using the adaptor primer.  As a result, 
only Hpa II-resistant DNA was amplified.  For the amplification of Msp I-cleaved 
(unmethylated plus methylated) DNA fragments, genomic DNA was digested with Msp 
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I followed by ligation to the adaptor. PCR was performed by using the adaptor primer.  
Amplified DNAs were labeled with Cy3 and Cy5 respectively, cohybridzed to the 
microarray with promoter regions of 288 cancer-related genes, scanned and analyzed. 
Cy3 intensity (Hpa II-resistant DNA fragments) was normalized to Cy5 intensity (Msp 
I-cleaved DNA fragments) for comparison among samples (normalized intensity = Cy3 
intensity /Cy5 intensity).  Normalized intensities of cancer and normal lungs were 
compared. 
 
Fig. 2  Eight genes were hypermethylated in five or more of the six lung cancer cell 
lines analyzed.  The PMAD results were confirmed by the COBRA method.   
 
Fig. 3 RT-PCR analyses of eight hypermethylated genes in Fig. 2.  Expression of 
ACTB (β-Actin) was monitored as an internal control.  
 
Fig. 4  Methylation analysis of five genes in primary tumours.  COBRA analysis was 
performed for IRF7, ASC, RIPK3, FABP3, and PAX3.  PCR primers and restriction 
enzymes used were the same as in Fig.2.  The present study was approved by the 
Ethics Committees of Tohoku University School of Medicine and Gunma University.  
Following a complete description of the research protocol, written informed consent 
was obtained from each participant. 
 
Table 1  Summary of the results for PMAD analysis.  Genes that were 
hypermethylated in at least two of six lung cancer cell lines are presented.  M 
represents hypermethylation in cancer defined as (Normalized intensity of cancer) / 
(Normalized intensity of normal) more than 3.0 when normalized intensity of cancer is 
high enough (more than 0.2).  NC represents an absence of hypermethylation in cancer 
defined as (Normalized intensity of cancer) / (Normalized intensity of normal) less than 
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3.0.  Results which do not meet the criteria of M and NC, such as Cy5 intensity less 
than background or normalized intensity of cancer less than 0.2, are represented as ND.   
 
Table 2  Proportion of hypermethylated genes in lung cancers. 
 
Supplementary Fig. 1  CpG maps of eight genes analyzed in Fig. 2.  Probe regions are 
presented.  Black and red circles indicate CpG and Hpa II sites, respectively. Black 
filled circles indicate the sites analyzed by COBRA analysis.  
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